About Pyros Pharma
Pyros Pharma is a Healthcare company based in New York (United States) founded in 2017, and was acquired by Bora Pharmaceuticals in October 2024. Pyros Pharma has raised $6.39 million across 2 funding rounds from investors including Bora Pharmaceuticals. Pyros Pharma offers products and services including VIGAFYDEâ„¢ (vigabatrin) and Specialty Pharmaceuticals. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is Pyros Pharmaceuticals, Inc.
Company details
Pyros Pharmaceuticals is a specialty pharmaceutical company focused on developing treatments for rare diseases, particularly those affecting infants and young children. The company is driven by a mission to elevate the standard of care for infantile spasms and is committed to making a meaningful difference in the lives of patients and families.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Website pyrospharma.com
- Social LinkedIn
- Acquired by Bora Pharmaceuticals (Oct 2024)
- Legal Name Pyros Pharmaceuticals, Inc
- Total Equity Funding$6.39M (USD)
in 2 rounds
- Latest Funding Round$450K (USD), Series A
Apr 2022
- Investors
- Acquired byBora Pharmaceuticals
(Oct 2024)
Products & Services of Pyros Pharma
Pyros Pharma offers a comprehensive portfolio of products and services, including VIGAFYDE™ (vigabatrin) and Specialty Pharmaceuticals.
A ready-to-use oral solution is provided for the treatment of infantile spasms
Enhanced pharmaceuticals are developed for rare diseases to improve treatment standards
Funding Insights of Pyros Pharma
Pyros Pharma has successfully raised a total of $6.39M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $450 thousand completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.39M
- Total Rounds 2
- Last Round Series A — $450,000
- First Round $5.94M
(Aug 2020)
All 2 funding rounds of Pyros Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $450,000 | Series A | – | – | – |
| Aug 2020 | $5.94M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Pyros Pharma
Pyros Pharma has secured backing from 1 investor. Prominent investors backing the company include Bora Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Traditional pharma company manufacturing and marketing a range of pharmaceutical products | 2008 | bora-corp.com | Taipei, Taiwan |
Investor details for Pyros Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pyros Pharma
5 people are tracked at Pyros Pharma (3 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Edwin Urrutia | Co-founder & Chief Operating Officer | Leadership |
Andy Tamulevich | Vice President of Sales | Leadership |
Shannon S. | National Sales Director West ~ Rare Disease Epilepsy, Neurology Division | Leadership |
Dominique Hetrick | Labeling & Publishing Associate Manager | Team |
Christine Janes | Senior Manager Quality and Compliance | Team |
Complete people profiles for Pyros Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pyros Pharma
4 dated milestones of Pyros Pharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Pyros Pharma is founded.
- Funding First funding round of $5.9M.
- Funding Latest funding round, Series A, of $450K.
- Exit Acquired by Bora Pharmaceuticals.
Web traffic of Pyros Pharma
The website of Pyros Pharma (pyrospharma.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 34.2% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Pyros Pharma (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pyros Pharma
Pyros Pharma was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Pyros Pharma is headquartered in New York, United States. It is registered at New York, New York, United States.
Pyros Pharma is a funded company, having raised a total of $6.39M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5.94M, raised on Aug 2020.
Pyros Pharmaceuticals is a specialty pharmaceutical company focused on developing treatments for rare diseases, particularly those affecting infants and young children. The company is driven by a mission to elevate the standard of care for infantile spasms and is committed to making a meaningful difference in the lives of patients and families.
Pyros Pharma offers VIGAFYDEâ„¢ (vigabatrin) and Specialty Pharmaceuticals.
Pyros Pharma has 1 investor. Key investors include Bora Pharmaceuticals.
Pyros Pharma operates through Pyros Pharmaceuticals, Inc.
Yes. Pyros Pharma was acquired by Bora Pharmaceuticals in October 2024.